ATLANTA, Sept. 9 /PRNewswire/ -- Celonova Biosciences, Inc. (“CeloNova”), a leading developer of innovative medical devices, today announced that the paper, “Comparison of late in-stent stenosis and vessel wall inflammation in Cypher(R) Select(TM), Taxus(R) Express(TM), and Polyzene(R)-F nanocoated cobalt chromium stents in a porcine coronary artery model” prepared by Dr. Boris Radeleff has been chosen to receive the CIRSE 2007 Magna Cum Laude EPOS Award.
“We are delighted that Dr. Radeleff has been honored by his peers for his work comparing the performance of the leading drug-eluting stents to a stent treated with CeloNova’s proprietary Polyzene(R)-F medically inert surface coating,” said Thomas A. Gordy, CeloNova President and Chief Executive Officer. “This award validates the high quality of the work undertaken by Dr. Radeleff and his colleagues to understand how Polyzene(R)-F can enhance the performance of coronary stents by inhibiting restenosis and thrombus formation without the need to resort to an anti-proliferative drug or long-term dual antiplatelet medications. We continue to believe, based on this and other ongoing research, that Polyzene(R)-F represents a revolutionary breakthrough in the quest to develop the ideal long-term solution for coronary stenting.”
Dr. Radeleff, a physician at the University Hospital of Heidelberg, received his award at the CIRSE Opening Ceremony and Awards Session in Athens, Greece on Saturday, September 08.
About CIRSE
The Cardiovascular and Interventional Radiological Society of Europe is a non-profit making, educational and scientific association of 2,300 interventional professionals with an active personal involvement and interest in interventional radiology or cardiovascular imaging techniques.
About CIRSE 2007
The CIRSE Annual Scientific and Postgraduate Educational Meeting has established itself as the premier gathering for all professionals devoted to the field of Cardiovascular and Interventional Radiology in Europe. CIRSE 2007 is a unique forum where medical professionals can meet their colleagues from all around the world, and exchange ideas and information in the field of minimally invasive, image guided therapies.
About CeloNova BioSciences, Inc.
Headquartered near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices based on the company’s patented Polyzene(R)-F surface coating technology. Polyzene(R)-F is highly lubricious, and possesses both anti-bacterial and anti-inflammatory properties that make it an ideal surface treatment for implanted medical devices. The company’s current product portfolio includes its Embozene(TM) Microspheres, used to treat arteriovenous malformations, hypervascularized tumors, uterine fibroids and hepatocellular carcinoma. Other innovative devices are currently in the company’s developmental pipeline. For more information, please visit www.celonova.com.
Contact: Thomas A. Gordy
President and Chief Executive Officer
+1 770-502-0304
CeloNova BioSciences, Inc.
CONTACT: Thomas A. Gordy, President and Chief Executive Officer ofCeloNova BioSciences, Inc., +1-770-502-0304
Web site: http://www.celonova.com/
